Gilead Sciences Inc

GILD

117.225USD

+1.975+1.71%

Market hours （ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

18 / 177

Overall Ranking

99 / 4730

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 30 analysts

Buy

Current Rating

125.252

Target Price

+8.68%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 814.79%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 814.79%.

Overvalued

The company’s latest PE is 22.76, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.12B shares, decreasing 1.06% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 118.78M shares of this stock.

The company's current financial score is 8.14, which is higher than the Pharmaceuticals industry's average of 6.80. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 6.67B, representing a year-over-year decrease of 0.28%, while its net profit experienced a year-over-year decrease of 131.53%.

Score

Industry at a Glance

Previous score

8.14

Change

0



Financials

9.14

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.62

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.72

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.22

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

8.01

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 1.80, which is higher than the Pharmaceuticals industry's average of 1.64. Its current P/E ratio is 22.50, which is 0.98% below the recent high of 22.72 and 2.37% above the recent low of 21.97.

Score

Industry at a Glance

Previous score

1.80

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 18/177

No Data

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.96. The average price target for Gilead Sciences Inc is 128.00, with a high of 143.00 and a low of 98.00.

Score

Industry at a Glance

Previous score

8.07

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 7.30, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 120.99 and the support level at 107.69, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.20

Change

-0.02

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-10

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.02. The latest institutional shareholding proportion is 90.01%, representing a quarter-over-quarter decrease of 0.15%. The largest institutional shareholder is The Vanguard, holding a total of 118.78M shares, representing 9.57% of shares outstanding, with 3.75% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

116.91M

+1.69%

BlackRock Institutional Trust Company, N.A.

70.66M

-5.11%

State Street Global Advisors (US)

59.52M

-1.42%

Fidelity Management & Research Company LLC

51.21M

+47.83%

Capital World Investors

53.55M

-25.32%

Wellington Management Company, LLP

27.36M

-23.28%

Capital Research Global Investors

54.61M

-5.76%

Dodge & Cox

Star Investors

32.69M

-0.77%

Geode Capital Management, L.L.C.

28.48M

+0.67%

Invesco Capital Management (QQQ Trust)

25.70M

-0.51%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 6.23, which is higher than the Pharmaceuticals industry's average of 3.51. The company's beta value is 0.38. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Gilead Sciences Inc

GILD

6.98 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

7.67 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.56 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.41 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BridgeBio Pharma Inc

BBIO

7.33 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Biogen Inc

BIIB

7.29 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.